✦ LIBER ✦

Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib

✍ Scribed by James C. Cusack

Book ID: 117487724
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 303 KB
Volume: 29
Category: Article
ISSN: 0305-7372
DOI: 10.1016/s0305-7372(03)00079-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Proteasome inhibitor bortezomib for the

Proteasome inhibitor bortezomib for the treatment of multiple myeloma

✍ Cavo, M 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 217 KB

Anti-Tumor Activity of the Proteasome In

Anti-Tumor Activity of the Proteasome Inhibitor Bortezomib in Gastric Cancer

✍ Nakata, Wachiko ;Hayakawa, Yoku ;Nakagawa, Hayato ;Sakamoto, Kei ;Kinoshita, Hir 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 80 KB

Hypoxia increases potency of the proteas

Hypoxia increases potency of the proteasome inhibitor VELCADETM (bortezomib) for injection: potential for a hypoxic cell cytotoxin in solid tumors

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Bortezomib, a novel proteasome inhibitor

Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies

✍ Graham Jackson; Hermann Einsele; Phillippe Moreau; Jesus San Miguel 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 239 KB

Bortezomib in the Treatment of Multiple

Bortezomib in the Treatment of Multiple Myeloma Volume 1106 || Second-Generation Proteasome Inhibitors

✍ Ghobrial, Irene M.; Richardson, Paul G.; Anderson, Kenneth C. 📂 Article 📅 2010 🏛 Springer Basel 🌐 German ⚖ 526 KB

Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promisin

Pulse treatment with the proteasome inhi

Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions

✍ P. Boissy; T.L. Andersen; T. Lund; K. Kupisiewicz; T. Plesner; J.M. Delaissé 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 303 KB

Myeloma bone disease is due to bone degradation by osteoclasts, and absence of repair by bone forming osteoblasts. Recent observations suggest that the anti-myeloma drug bortezomib, a proteasome inhibitor, stimulates bone formation and may inhibit bone resorption. Here, we tested bortezomib on cultu